WASHINGTON (AP) — An experimental drug might help slow early Alzheimer’s disease in a markedly different way than today’s treatments — by lowering levels of a brain protein called tau,
WASHINGTON (AP) — An experimental drug might help slow early Alzheimer’s disease in a markedly different way than today’s treatments — by lowering levels of a brain protein called tau, researchers reported Tuesday.
Tau is one part of a toxic duo fueling Alzheimer’s but prior attempts to develop drugs that can target the protein have failed. Two Alzheimer’s drugs, lecanemab and donanemab, try to clear buildup of the better-known amyloid protein and can modestly slow cognitive decline.
An experimental Alzheimer's drug shows some promise as researchers hunt new approaches
Experimental Alzheimer's drug shows some promise as researchers hunt new approaches
New experimental drug shows promise in slowing early Alzheimer’s
New experimental Alzheimer's drug shows potential after study shows slower cognitive decline | Fortune
Novel Alzheimer's Drug Targeting Tau Shows Promise in Mid-Stage Trial
Rare Brain Autopsy Hints at Why Alzheimer's Drugs Are Failing
An experimental drug might help slow early Alzheimer's disease in a markedly different way than current treatments — by lowering…
An experimental drug might help slow early Alzheimer's disease in a markedly different way than current treatments — by lowering…
An experimental drug might help slow early Alzheimer's disease in a markedly different way than current treatments — by lowering…
A study on Biogen's diranersen found it slowed cognitive decline and has promise in treating Alzheimer's disease, researchers…
Biogen said signals sugget the treatment decreases levels of tau and slows cognitive decline, particularly at the lowest dose.
Researchers hope findings could help delay symptoms by five or six years
